Testing Immunotherapies in Syngeneic Models
Charles River offers a broad range of syngeneic tumor models with well-characterized responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1 and anti-CTLA-4), making us the ideal partner to advance your immuno-oncology pipeline.
|SYNGENEIC MODEL DATA|
Access our syngeneic model data including check point inhibitor and whole exome sequencing (WES).
SYNGENEIC MODELS WITH PROFILE
Histotype Cell Line Bladder MBT-2 Brain GL261 Breast 4T1, EMT-6 Colon Colon26, CT26, MC38 Lung KLN 205, Lewis Lung, Madison109 Lymphoma A20, E.G7-OVA Melanoma B16F10, CloudmanS91 Pancreatic Pan02 Renal Renca
SYNGENEIC MODELS WITHOUT PROFILE*
Histotype Cell Line Breast EMT-6-BRCA1(−/−), EMT-6-BRCA1(+/−), 4T1-BRCA1(+/−) Hepatoma Yoshida Leukemia C1498, L1210, P388 Lymphoma EL4 Mastocytoma P815 Plasmacytoma J558 Sarcoma EHS
* Note: Although these models have not yet been profiled for response to current standards of care, tumor growth curve data is available.